GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (STU:UP0) » Definitions » Additional Paid-In Capital

Ultragenyx Pharmaceutical (STU:UP0) Additional Paid-In Capital : €3,403.0 Mil(As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Ultragenyx Pharmaceutical Additional Paid-In Capital?


Ultragenyx Pharmaceutical's quarterly additional paid-in capital increased from Sep. 2023 (€3,090.6 Mil) to Dec. 2023 (€3,358.4 Mil) and increased from Dec. 2023 (€3,358.4 Mil) to Mar. 2024 (€3,403.0 Mil).

Ultragenyx Pharmaceutical's annual additional paid-in capital increased from Dec. 2021 (€2,652.8 Mil) to Dec. 2022 (€2,964.2 Mil) and increased from Dec. 2022 (€2,964.2 Mil) to Dec. 2023 (€3,358.4 Mil).


Ultragenyx Pharmaceutical Additional Paid-In Capital Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Additional Paid-In Capital Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,878.18 2,279.57 2,652.79 2,964.18 3,358.37

Ultragenyx Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,960.19 2,987.64 3,090.56 3,358.37 3,403.04

Ultragenyx Pharmaceutical Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Ultragenyx Pharmaceutical Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical (STU:UP0) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (STU:UP0) Headlines

No Headlines